APC unveils €25m investment and 120 jobs to accelerate development and manufacture of Covid Vaccines and Advanced Therapeutics.
APC welcomed Irish Prime Minister to discuss fast-tracking a COVID-19 vaccine with Australian firm Vaxine, showcasing our role in advancing vital medicines.
We take privacy and the management of your data very seriously. Read about our cookie policy.
Biostór and VLE Therapeutics have established a strategic alliance to deliver an end-to-end (E2E) cell banking solutions. This post outlines the detailed process of our collaboration, from initial consultation to final delivery, emphasizing the integration of our services.
Irish R&D firm APC partners with Australian biotech Vaxine to speed up COVID-19 vaccine candidate development, accelerating the time to patients.
As perpetual innovators and disruptors in the process development space, we’re constantly cultivating new talent and enhancing our capabilities.
We take privacy and the management of your data very seriously. Read about our protocols.
ATMP's represent an area of burgeoning development and rapid growth in the pharma industry. But manufacturing infrastructure & capacity must keep pace
As perpetual innovators and disruptors in the process development space, we’re constantly cultivating new talent and enhancing our capabilities.
APC & VLE Therapeutics, the Irish Multinational group, announce €100M expansion and 300 new jobs to establish ‘The Medicine Accelerator Campus’ in Cherrywood, Dublin
APC & VLE Therapeutics, the Irish Multinational group, announce €100M expansion and 300 new jobs to establish ‘The Medicine Accelerator Campus’ in Cherrywood, Dublin
We are thrilled to announce that APC will host the 25th ACT Larson Workshop from September 29th to October 2nd, 2024, at The Royal Sonesta Boston in Cambridge, Massachusetts. This event will gather leading experts in crystallization for a unique and engaging 2.5-day workshop, focused on academic-industrial exchange.
CEO & Co-founder Mark Barrett reveals how The Medicine Accelerator is transforming medicine development in 2025 with €100M campus expansion, AI-driven iAchieve®, and deep-tech innovation.
Our process development approach centres on science-first coupled with radical collaboration - pushing ourselves & our clients to deliver for patients faster.
[WEBINAR] Delve into APC’s Continuous Manufacturing philosophy, especially the use of continuous crystallization, modeling, design and PAT applications.
Mark Barrett, CEO shares reflections ahead of some exciting developments to be announced in early 2024.
The Medicine Accelerator (APC and VLE Therapeutics) has been recognized as one of Ireland’s Top 100 Companies for Workplace Wellbeing by Business & Finance and Ibec—highlighting its commitment to fostering a healthy, high-performing workplace through the BeWell@Cherrywood initiative and KeepWell™ accreditation.
The Medicine Accelerator is expanding its digital business with strategic new roles to scale iAchieve®—a first-of-its-kind digital CMC platform built on 100,000s of expert-led experiments and thousands of contextualized programs—to accelerate medicine development and manufacturing globally.
October 22 2025: Minister for Further and Higher Education, Research, Innovation and Science, James Lawless TD has today announced a €2million co-funded investment by APC Ltd and Research Ireland. To be funded for the next five years, TRANS-AM is a collaborative research partnership between APC Ltd, the National Institute for Bioprocessing Research and Training (NIBRT), and University College Dublin (UCD), and is focused on advanced biotherapeutics.
We will be at booth #99 Oct 29-31, 2024 in Barcelona to discuss your vaccine development and manufacturing challenges. Don't miss the technical presentation from our experts.
See how CrysAI™ applies deep learning to crystallization and cell imaging—automating segmentation, improving reproducibility, and scaling insight.
Our science-first approach prioritizes quality process development to accelerate the delivery of medicines to patients | Process Portability | True Transparency.
APC and VLE Therapeutics are delighted to announce the commencement of the initial phase of The Medicine Accelerator Campus expansion. Following the planning submission for the campus, the initial mobilization for the construction of the Campus Greenway has begun by Dun Laoghaire Rathdown County Council.
Explore how digital tools like process modeling, PAT, and digital twins are reshaping HPAPI development. Learn how pharmaceutical teams are using real-time data and virtual experimentation to design safer, faster, and more reliable high-potency manufacturing processes.
Visit our unique “Medicine Accelerator” facility in Dublin where we’re redefining the future of pharmaceutical manufacturing through our unwavering commitment to a groundbreaking concept – "Process Advancing Medicine."
Collaboration between Takeda and APC will design, optimize and deliver process improvements for Takeda’s portfolio of biologics-based medicines.
Building on this foundation, APC announces a strategic partnership with METTLER TOLEDO AutoChem, a global leader in automated reactor technology, process analytical tools (PAT), and chemical development software platforms. Together, the partnership seeks to build a fully integrated digital development environment—advancing how data, decisions, and design converge across the full CMC lifecycle.
APC and NIBRT join forces, expanding client access to biopharmaceutical services, enhancing process development and analytical capabilities.
APC and VLE are set to exhibit at Biotech Week in Boston, September 27-30th. Visit us at booth 1007!
APC and VLE are set to exhibit at World Vaccine Congress. Don’t miss the live presentation, ‘Model-driven transfection and transduction optimization’.
APC and VLE are set to exhibit at BOS Basel, July 4-5. Visit us at booth 42!
Smarter DoEs, Recipe Definition, Reactor Design, & Crystallization - Pharmaceutical Process Modelling Ensures the Most is Made from Every Experiment. Learn how.
Our expert, Dr. Jacek Zeglinski talks about the various challenges which drug substance developers face when seeking to develop material suitable for tabletting
Optimizing cell culture media directly impacts cell growth, yield, and biotherapeutic quality, enhancing productivity and cost-efficiency.
This case study highlights the significance of particle size analysis via Dynamic Light Scattering (DLS) in the development of vaccines based on the MVA virus.
This study introduces a hybrid method combining the COSMO-RS model with machine learning to predict aqueous solubility at room temperature.
This on-demand webinar from APC explores how Crystallization-Induced Diastereomeric Transformation, or CIDT, can improve diastereomeric salt crystallization for chiral resolution. The session covers solubility behavior, phase relationships, counterion selection, solvent choice, solid-state control, and analytical strategies for improving enantiomer separation. It is relevant for pharmaceutical development teams working on chiral molecules, double salts, crystallization process design, yield improvement, purity optimization, scale-up, and enantiopure compound production.
We take privacy and the management of your data very seriously. Read about our protocols.
APC has joined the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) as one of the 26 industrial partners.
HPRA is baseline. An integrated PD→GMP model with a single digital backbone improves clinical readiness, shortening time to batch start and boosting right-first-time.
Fast & effective analytical method transfer of Final Product, APIs, Bulk Drug, Drug Substance (DS), Drug Product (DP), Intermediates, and more! Learn how.
APC's Cherrywood HQ creates 100 jobs, partners with pharma giants. CEO Mark Barrett highlights the complexity of translating molecules into medicines.
Avoid FDA Complete Response Letters (CRLs) by focusing on a strong CMC strategy, deep process understanding, and scientific excellence to ensure smoother drug approvals.
APC & VLE Therapeutics is looking forward to seeing you at World Vaccine Congress, in Amsterdam which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
Your medicine’s success is paramount. Our state-of-the-art synthetic & biologic labs are tailored to optimize processes for you. Take a tour today!
APC was created out of a passion for science and research. Learn more about Our Story, Our Team, & Our Culture.
APC & VLE Therapeutics have been named BioPharma Company of the Year, recognising The Medicine Accelerator’s Irish-led approach to process science, digital CMC, and GMP-ready medicine development.
A lack of process understanding & control leads to: inability to scale, product quality drift, & costly delays from batch failures & regulatory concerns
A Proprietary, digital platform built to transform your CMC | Capture, Curate, & Collaborate on all CMC decisions with experimental data underpinning them.
Applied Process Company Ltd. opens a research facility creating 100 new jobs for Ireland.
Applied Process Company Ltd. is a Dublin based pharmaceutical R&D company using revolutionary technology to help pharmaceutical companies bring new medicines to the market quickly.
Computational methods play an increasingly important role in all stages of drug development and when used judiciously can help accelerate the timelines required to get over various process and manufacturing hurdles.
We’re delighted to announce that APC has received Deloitte's 'Ireland's Best Managed Company Award' at a gala in Dublin on September 14, 2023. This award is given based on a company's overall success, including its company culture, management strength, capacity for innovation, strategic initiatives, sustainability, and financial performance.
Ireland becomes a top location for pharmaceutical research and developing future drugs.
The Medicine Accelerator joins Manufacturing Day Ireland on 3 October, hosting future innovators to explore careers in science, technology, and advanced manufacturing.
APC & VLE Therapeutics is looking forward to seeing you at AIChE, in Boston which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
Applied Process Company Ltd. welcomes committee members from The Pharmaceutical Manufacturing Technology Centre (PMTC). Pursuing a common vision to make Ireland the global hub of pharmaceutical process innovation.
APC and Bavarian Nordic invest €2M in scalable RSV vaccine process with a 500L facility, PAT, Process Modelling, ensuring robust and transferable manufacturing.
APC & VLE Therapeutics is looking forward to seeing you at Biotech Outsourcing Strategies on November 26-27th, 2024 in Manchester!
Industry Veteran Brett Huff has joined APC to head up our First-in-Class Digital Strategy for process development.
A Message from the APC Team to Collaborators, "Now, more than ever, collaboration is vital."
Scale-up complexity arises from reactor configuration & engineering correlations. CFD can be used to model bespoke systems, matching shear stress across scales.
APC & VLE founders Mark Barrett & Brian Glennon, receive Pharma Leader award for their innovative global centre of excellence in process dev & manufacturing.
Decoupling process development from manufacturing enhances control, flexibility and innovation - accelerating time to market and reducing risks in pharmaceutical development.
This paper explores the development of a chromatography-based platform process for adeno-associated virus (AAV) purification, focusing on exploiting AAV characteristics and addressing impurities to enable scalable and standardized gene therapy manufacturing.
This on-demand webinar from The Medicine Accelerator examines how ATMP developers can move from lab-scale development toward GMP manufacturing with stronger process understanding, quality control, and technology transfer planning. The session focuses on an oncolytic virus case study that achieved a 400% increase in viral yield and a 90% reduction in cost per dose. Topics include ATMP process development, upstream and downstream optimization, impurity profile improvement, manufacturability, GMP readiness, regulatory considerations, tech transfer, clinical manufacturing capacity, and faster time to patient.
Expert strategies for rapid biopharma cell line selection that delivers on process performance & product quality. Learn about our fast & collaborative approach.
FDA’s 2025 approvals show biologics growing more complex. Learn why next-gen modalities demand stronger analytics, process design, and integrated CMC strategies.
A "science-first" philosophy facilitates unrivalled insights & understanding and allows a full characterization of your process across all unit ops.
Bayesian Optimization provides a more efficient alternative to traditional Design of Experiments (DoE) for process development, particularly when navigating multiple factors and levels. This case study highlights an innovative approach involving the exploration of areas characterized by high uncertainty and high potential yield. This focus enabled the identification of optimal operating ranges for critical factors, ultimately maximizing reaction yield.
The 2016 Applied Process Company Ltd. year in review.
At APC, we’re very proud of the fact that we help companies accelerate the development of therapeutics for rare diseases.
[WEBINAR] Experts review challenges, proven strategies for tech transfer, & an unique approach using digitalization, process optimization, & risk management.
APC & VLE Therapeutics is looking forward to seeing you at BIO International Convention, in Boston which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at Blueprint: Digital Engineering Talk which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at BOS Basel, in Basel which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at Biomanufacturing World Summit, in San Diego which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at Advancing Drug Development Forum, in Boston which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
CRLs often stem from hidden knowledge gaps. Discover how iAchieve® turns tacit expertise into traceable CMC logic to strengthen submissions and reduce risk.
The Medicine Accelerator is thrilled to exhibit at Advanced Therapies, London 2026! Stop by and say hello!
APC & VLE Therapeutics is looking forward to seeing you at CPHI, in Tokyo which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at PD2M, in Cambridge, MA which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at Bioprocess International Europe, in Vienna which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
Small molecules still dominate FDA approvals, but rising stereochemical and solid-state complexity demands stronger CMC strategies for 2026 readiness.
APC Expanded its US Presence with New Offices in Cambridge, MA
The recent wave of CDMO acquisitions, COVID-19, and global geopolitical uncertainty has underscored the need for pharmaceutical companies to future-proof their manufacturing operations against potential disruptions. In such a climate, Process Portability emerges as a strategic imperative, offering pharmaceutical companies a proactive approach to safeguarding their operations.
APC Hosted a Complimentary Workshop in Partnership With Nucleo Life Sciences on Technology Innovations in API and Drug Product Formulation Development.
Discover the industry drivers for Continuous Processing and how it accelerates development and benefits your manufacturing strategy.
APC's information partnership approach offers in-depth process understanding, reducing outsourcing dependency.
We will be at booth 77 Oct 16-19, 2023 in Barcelona to discuss your vaccine development and manufacturing challenges. Don't miss the presentation and technical poster from our technical experts.
Our group CEO, Mark Barrett (APC & VLE) & COO, Paul McCabe (VLE) will be presenting at BioPharmaChem Impact 24. Looking forward to seeing you on May 23rd.
Michael Jordan is widely regarded as the greatest basketball player of all time. But beyond his athletic prowess, his philosophy offers invaluable lessons for CMC professionals. Discover how the principles that guided MJ’s legendary career can be applied in pharmaceutical manufacturing.
Join us at Biomanufacturing World Summit, San Diego at booth # 13 to meet one-on-one and discuss your development and manufacturing challenges and our approach to accelerating your medicines through CMC hurdles.
The Medicine Accelerator proudly announces its triple win at the 2024 Pharma Industry Awards, securing Biotech Company of the Year, Pharma Company of the Year - SME, and Pharma Industry Company of the Year. Shortlisted in eight categories, APC and VLE stood out for their excellence in scientific innovation, operational performance, sustainability, and talent development.
APC & VLE Therapeutics is looking forward to seeing you at Bioprocessing Summit Europe which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
Explore these innovative approaches undertaken by APC in addressing the challenges of peptide crystallization .
A fundamental understanding of critical process parameters in the upstream unit ops is crucial in the development of your biotherapeutic. Learn how we can help.
Process Analytical Technology (PAT) + Automation + Data Mgmt + Process Development Experts = Insights that Deliver First-Right-Time Results. Learn how.
Automated assembly of hybrid dynamic models for CHO cell culture processes. Doyle, K., Tsopanoglou, A., Fejér, A., Glennon, B., & del Val, I. J. (2023)
CHO cells are pivotal for mAb production. The use of PAT e.g. Raman spectroscopy can help optimize processes, reducing time-to-market and costs.
Meet us at BOS Basel on June 20th at booth no: 17!
A comprehensive development history is vital for addressing CMC queries. Digitalization ensures an accurate and complete CMC story for every medicine.
[WEBINAR] Learn how mechanistic modelling + CFD to understand and optimize transfection and transduction efficiency can increase yield and lower costs.
A Chinese Hamster Ovary (CHO) mammalian cell process moved to a PAT-enabled continuous feed strategy to prevent nutrient loss & stabilize the macroenvironment.
Using data-rich experimentation and mixing models, which leverage CFD, a right-first scale up of the new process was achieved within the yield improvements translating directly back to the plant.
[PANEL DISCUSSION] CMC data is often fragmented, siloed and lacks context - causing regulatory bottlenecks, manufacturing delays & quality issues.
Learn more about Nobel-prize winner Barry Sharpless and his impact on modern chemistry.
For the synthesis & crystallization of APIs, Mixed Suspension Mixed Product Removal Crystallizers (MSMPRCs) can help address common issues in batch production.
The Medicine Accelerator is thrilled to exhibit at Gene Therapy Development 2024. Stop by and say hello!
The Medicine Accelerator is thrilled to exhibit at Biochemical and Molecular Engineering XXIII, 2024. Stop by and say hello!
APC & VLE Therapeutics is looking forward to seeing you at booth #105 March 18th-19th, 2025 in London!
APC & VLE Therapeutics is looking forward to seeing you, March 17th-19th, 2025 in Milan!
APC & VLE Therapeutics is looking forward to seeing you March 18th-19th, 2025 in Barcelona!
In this presentation, Alexandra Bogdanovic, from APC’s bioprocess development team, delves into some of the key challenges and strategies associated with AAV production optimization.
The Medicine Accelerator is thrilled to exhibit at 52nd Organic Process Research and Development Conference, 2024. Stop by and say hello!
The Medicine Accelerator is thrilled to exhibit at Bioprocess International, 2024. Stop by and say hello!
Capturing & curating the data underpinning CMC decisions across the development life of your biomolecule can be a significant challenge. Learn how we can help.
Optimize challenging steps related to process & product performance, with flexible options that never lock you into a single manufacturing approach or vendor.
Applied Process Company Ltd. creates ne markets with the developed of ACHIEVE and BioACHIEVE, for troubleshooting research and manufacturing issues and improving the design of chemical and biopharmaceutical compounds.
When not fully addressed, protein aggregation can slow development. Learn 5 methods to ensure a full understanding of key processes.
[WEBINAR] Industry bottlenecks in drug substance development: solubility, particle size, and morphology.
Discover how Computational Fluid Dynamics (CFD) helps de-risk scale-up and optimize biopharmaceutical manufacturing. Learn how CFD reveals hidden mixing dynamics, supports tech transfer, improves efficiency, and ensures regulatory-ready process insights.
Trial & error is not an efficient way to solve filtration, washing, and drying challenges. Partnering with solid state chemistry and engineering experts is!
A laser-like focus on process development significantly reduces the time to get medicines to patients. Learn about our "Process Advancing Medicine" approach.
APC wins the 2018 Biotech Company of the Year award.
APC’s CEO Dr Mark Barrett, discusses Ireland’s involvement in the pharmaceutical industry and APC’s current plans on developing a COVID-19 vaccine in partnership with Vaxine Pty Ltd.
Harnessing the power of CFD to optimize process equipment cleaning protocols
[WEBINAR] Accelerate development without comprising on quality! Dr Hasbullah Daud discusses how - using PAT, modelling, & cutting-edge analytical techniques.
In this webinar, we will explore the development of a 2nd generation downstream process for a complex biotherapeutic and discuss strategies to significantly reduce the number of unit operations, increase yields, reduce costs, and accelerate time-to-market while meeting CQA specifications.
APC & VLE Therapeutics is looking forward to seeing you at Bioprocessing Summit, in Barcelona which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at DCAT, a premier global event based in NYC where biopharmaceutical development and manufacturing professionals gather to convene, forge connections, brainstorm, and foster collaboration for the upcoming year.
Looking forward to seeing you at PDSM on May 21-22 in Boston. Excited to have a technical presentation on "Model-Driven Transfection Process Development" by Ana L. P. Luiza, Senior Process Development Engineer and Panel Discussion on "Modeling and Simulation in Pharmaceutical Development and Manufacturing" presented by Brian Glennon, CTO & others.
Looking forward to meet you one-on-one to discuss your development and manufacturing challenges on May 28th.
The Medicine Accelerator is thrilled to exhibit at Highly Potent Drugs Summit 2024. Stop by and say hello!
APC scientists developed an approach to enantiomeric crystallization process development that combines building a ternary phase diagram with PAT enabled kinetic profiling to unlock the thermodynamic and kinetics insights needed to support ultra-fast process development for these challenging crystallization processes.
The Medicine Accelerator is thrilled to exhibit at Lab of the Future Europe, 2024. Stop by and say hello!
Be sure to check out these insightful technical presentations and meet our experts at Booth #714
APC & VLE Therapeutics is looking forward to seeing you at BIO-Europe, in Sweden.
We’ve curated a list of key crystallization publications from the past 25 years, showcasing the research and breakthroughs that have defined our approach and expertise. These publications represent the culmination of decades of innovative work by APC’s crystallization experts, illustrating our ongoing impact in this field.
APC & VLE Therapeutics is looking forward to seeing you at Bioprocessing Summit, in Barcelona which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC & VLE Therapeutics is looking forward to seeing you at this CLS event in San Diego which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.
APC’s Powder Drying Optimization approach reframes drying as a controllable design variable, using analytics and modelling to improve speed, yield, and reliability.
At APC and VLE Therapeutics, we take great pride in our role in advancing the development of therapeutics for rare diseases.
Gain confidence in your process's scalability using scale-down approaches which offer insights to optimize it according to your specific reactor needs.
Harness the power of our continuous processing expertise to develop greener, safer processes with smaller manufacturing footprints.
Accelerate your synthetic modality development and launch with an engineering-centric approach to process chemistry, whether classic or highly potent.
Applied Process Company Ltd. wins in the Bioscience Category at the Irish Times Innovation Awards.
Learn how optimize a reaction using engineering first principles
Process portability is a concept pioneered by APC which encompasses the capability to seamlessly transfer robust manufacturing processes across different facilities or locations without compromising product quality or efficiency
Tour our labs with our process development experts and scientific thought-leaders | In-person or Virtual Tours Available
The new Applied Process Company Ltd. facility creates 100 new jobs for Ireland.
Applied Process Company Ltd. is featured at the #GlobalAmbition Campaign.
Applied Process Company Ltd. wins Pharma Company of the Year award.
Rising Star! Applied Process Company Ltd. is one of the top health science start-ups to watch.
Predicting the percolation threshold, using statistical models or experimentation, is an evidence-based approach that can get solid dosage forms designed faster.
[WEBINAR] Good crystallization process design, can save months of development time. But, crystallization of stereoisomers can be particularly challenging.
[WEBINAR] Scale-up of crystallization processes is rarely trivial & often necessitates careful consideration and in-depth understanding of process parameters.
In this case study, operating temperatures had an impact on process performance attributes and product quality resulting in a variable purification step.
In this study, the final purification step of a mAb was resulting in significant yield loss (up to 50%). Learn how experts redefined this problematic process.
APC participated at Bioprocessing summit in the Seaport World Trade Center.
APC & VLE set to give talks during ‘Particle Agglomeration & Granulation Processes’ & ‘Particle Technology in Product Design & Manufacturing’ sessions.
Tech transfer of Advanced Therapy Medicinal Products (ATMPs) presents additional challenges beyond those faced when transferring more traditional biologics.
Good analytic method development is crucial for smooth and efficient process development. Learn how our world-class analytical team can help.
Expand your choice of reactors and platform needed to manufacture your biotherapeutic by leveraging unique microcarrier process development capabilities.
Choosing the optimal solvent (or solvent combination) for your API can be experimentally intense. See how AI-driven solubility modelling can be a game changer.